157 related articles for article (PubMed ID: 10992527)
1. Enterotoxin-specific immunoglobulin E responses in humans after infection or vaccination with diarrhea-causing enteropathogens.
Qadri F; Asaduzzaman M; Wennerås C; Mohi G; Albert MJ; Abdus Salam M; Sack RB; Jertborn M; McGhee JR; Sack DA; Holmgren J
Infect Immun; 2000 Oct; 68(10):6077-81. PubMed ID: 10992527
[TBL] [Abstract][Full Text] [Related]
2. Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers.
Islam K; Hossain M; Kelly M; Mayo Smith LM; Charles RC; Bhuiyan TR; Kováč P; Xu P; LaRocque RC; Calderwood SB; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB; Qadri F; Ryan ET
PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006376. PubMed ID: 29624592
[TBL] [Abstract][Full Text] [Related]
3. Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139.
Kamruzzaman M; Kelly M; Charles RC; Harris JB; Calderwood SB; Akter A; Biswas R; Kaisar MH; Bhuiyan TR; Ivers LC; Ternier R; Jerome JG; Pfister HB; Lu X; Soliman SE; Ruttens B; Saksena R; Mečárová J; Čížová A; Qadri F; Bystrický S; Kováč P; Xu P; Ryan ET
mSphere; 2021 Aug; 6(4):e0011421. PubMed ID: 34232076
[TBL] [Abstract][Full Text] [Related]
4. Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine.
Jertborn M; Svennerholm AM; Holmgren J
Vaccine; 1996 Oct; 14(15):1459-65. PubMed ID: 8994322
[TBL] [Abstract][Full Text] [Related]
5. Concomitant enterotoxigenic Escherichia coli infection induces increased immune responses to Vibrio cholerae O1 antigens in patients with cholera in Bangladesh.
Chowdhury F; Begum YA; Alam MM; Khan AI; Ahmed T; Bhuiyan MS; Harris JB; LaRocque RC; Faruque AS; Endtz H; Ryan ET; Cravioto A; Svennerholm AM; Calderwood SB; Qadri F
Infect Immun; 2010 May; 78(5):2117-24. PubMed ID: 20176796
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.
Tacket CO; Cohen MB; Wasserman SS; Losonsky G; Livio S; Kotloff K; Edelman R; Kaper JB; Cryz SJ; Giannella RA; Schiff G; Levine MM
Infect Immun; 1999 Dec; 67(12):6341-5. PubMed ID: 10569747
[TBL] [Abstract][Full Text] [Related]
7. Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease.
Jertborn M; Svennerholm AM; Holmgren J
J Clin Microbiol; 1986 Aug; 24(2):203-9. PubMed ID: 3528211
[TBL] [Abstract][Full Text] [Related]
8. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection.
Losonsky GA; Tacket CO; Wasserman SS; Kaper JB; Levine MM
Infect Immun; 1993 Feb; 61(2):729-33. PubMed ID: 8423098
[TBL] [Abstract][Full Text] [Related]
9. Concomitant infection of enterotoxigenic Escherichia coli in an outbreak of cholera caused by Vibrio cholerae O1 and O139 in Ahmedabad, India.
Chakraborty S; Deokule JS; Garg P; Bhattacharya SK; Nandy RK; Nair GB; Yamasaki S; Takeda Y; Ramamurthy T
J Clin Microbiol; 2001 Sep; 39(9):3241-6. PubMed ID: 11526157
[TBL] [Abstract][Full Text] [Related]
10. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
[TBL] [Abstract][Full Text] [Related]
11. Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine.
Tokuhara D; Yuki Y; Nochi T; Kodama T; Mejima M; Kurokawa S; Takahashi Y; Nanno M; Nakanishi U; Takaiwa F; Honda T; Kiyono H
Proc Natl Acad Sci U S A; 2010 May; 107(19):8794-9. PubMed ID: 20421480
[TBL] [Abstract][Full Text] [Related]
12. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
[TBL] [Abstract][Full Text] [Related]
13. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.
Roland KL; Cloninger C; Kochi SK; Thomas LJ; Tinge SA; Rouskey C; Killeen KP
Vaccine; 2007 Dec; 25(51):8574-84. PubMed ID: 18045752
[TBL] [Abstract][Full Text] [Related]
14. Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers.
Morris JG; Losonsky GE; Johnson JA; Tacket CO; Nataro JP; Panigrahi P; Levin MM
J Infect Dis; 1995 Apr; 171(4):903-8. PubMed ID: 7706818
[TBL] [Abstract][Full Text] [Related]
15. Lipopolysaccharide- and cholera toxin-specific subclass distribution of B-cell responses in cholera.
Qadri F; Ahmed F; Karim MM; Wenneras C; Begum YA; Abdus Salam M; Albert MJ; McGhee JR
Clin Diagn Lab Immunol; 1999 Nov; 6(6):812-8. PubMed ID: 10548569
[TBL] [Abstract][Full Text] [Related]
16. A rice-based oral cholera vaccine induces macaque-specific systemic neutralizing antibodies but does not influence pre-existing intestinal immunity.
Nochi T; Yuki Y; Katakai Y; Shibata H; Tokuhara D; Mejima M; Kurokawa S; Takahashi Y; Nakanishi U; Ono F; Mimuro H; Sasakawa C; Takaiwa F; Terao K; Kiyono H
J Immunol; 2009 Nov; 183(10):6538-44. PubMed ID: 19880451
[TBL] [Abstract][Full Text] [Related]
17. A review of the current status of enteric vaccines.
Levine MM; Noriega F
P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.
Raghava Mohan V; Raj S; Dhingra MS; Aloysia D'Cor N; Singh AP; Saluja T; Kim DR; Midde VJ; Kim Y; Vemula S; Narla SK; Sah B; Ali M
PLoS One; 2019; 14(6):e0218033. PubMed ID: 31211792
[TBL] [Abstract][Full Text] [Related]
19. The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae.
Mayo-Smith LM; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Calderwood SB; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB
Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27847368
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.
Saha A; Chowdhury MI; Khanam F; Bhuiyan MS; Chowdhury F; Khan AI; Khan IA; Clemens J; Ali M; Cravioto A; Qadri F
Vaccine; 2011 Oct; 29(46):8285-92. PubMed ID: 21907255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
